Dec 28, 2023 5:00pm EST Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Dec 11, 2023 8:01am EST Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Nov 29, 2023 4:27pm EST Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Nov 29, 2023 7:59am EST Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Nov 09, 2023 7:59am EST Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Sep 07, 2023 4:14pm EDT Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Aug 01, 2023 7:59am EDT Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
Jul 20, 2023 8:43am EDT Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
